Publications by authors named "Benjamin Hanfstein"

Claim this Profile
gene expression at diagnosis does not predict for outcome of chronic myeloid leukemia patients on imatinib treatment.
Damla Buket Egeli, Benjamin Hanfstein, Michael Lauseker, Markus Pfirrmann, Susanne Saussele

Leuk Lymphoma· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic importance of expression of the Wilms' tumor 1 gene in newly diagnosed acute promyelocytic leukemia.
Anna Hecht, Florian Nolte, Daniel Nowak, Verena Nowak, Mark Reinwald, Benjamin Hanfstein

Leuk Lymphoma· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML.
Alice Fabarius, Lida Kalmanti, Christian T Dietz, Michael Lauseker, Sébastien Rinaldetti, Benjamin Hanfstein

Ann Hematol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A molecular risk score integrating BAALC, ERG and WT1 expression levels for risk stratification in acute promyelocytic leukemia.
Anna Hecht, Daniel Nowak, Verena Nowak, Benjamin Hanfstein, Thomas Büchner

Leuk Res· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.
Susanne Saussele, Marie-Paloma Krauss, Rüdiger Hehlmann, Michael Lauseker, Ulrike Proetel, Benjamin Hanfstein

Blood· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response-related predictors of survival in CML.
Benjamin Hanfstein, Martin C Müller, Andreas Hochhaus

Ann Hematol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase.
Michael Lauseker, Benjamin Hanfstein, Claudia Haferlach, Susanne Schnittger, Markus Pfirrmann

J Cancer Res Clin Oncol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.
Benjamin Hanfstein, Michael Lauseker, Rüdiger Hehlmann, Susanne Saussele, Philipp Erben

Haematologica· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.
Ulrike Proetel, Nadine Pletsch, Michael Lauseker, Martin C Müller, Benjamin Hanfstein

Ann Hematol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.
Rüdiger Hehlmann, Martin C Müller, Michael Lauseker, Benjamin Hanfstein, Alice Fabarius

J Clin Oncol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.
Lida Kalmanti, Susanne Saussele, Michael Lauseker, Ulrike Proetel, Martin C Müller, Benjamin Hanfstein

Ann Hematol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High expression of the Ets-related gene (ERG) is an independent prognostic marker for relapse-free survival in patients with acute promyelocytic leukemia.
Anna Hecht, Daniel Nowak, Verena Nowak, Benjamin Hanfstein, Andreas Faldum

Ann Hematol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In acute promyelocytic leukemia (APL) low BAALC gene expression identifies a patient group with favorable overall survival and improved relapse free survival.
Florian Nolte, Anna Hecht, Mark Reinwald, Daniel Nowak, Verena Nowak, Benjamin Hanfstein

Leuk Res· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.
Eva Lengfelder, Benjamin Hanfstein, Claudia Haferlach, Jan Braess, Utz Krug

Ann Hematol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3.
Daniel Nowak, Marion Klaumuenzer, Benjamin Hanfstein, Maximilian Mossner, Florian Nolte

Genes Chromosomes Cancer· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
Nicolai Härtel, Thomas Klag, Benjamin Hanfstein, Martin C Mueller, Thomas Schenk

J Cancer Res Clin Oncol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.
Alice Fabarius, Armin Leitner, Andreas Hochhaus, Martin C Müller, Benjamin Hanfstein

Blood· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
Philipp Erben, Philipp Ströbel, Karoline Horisberger, Juliana Popa, Beatrice Bohn, Benjamin Hanfstein

Int J Radiat Oncol Biol Phys· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy.
Benjamin Hanfstein, Martin C Müller, Sebastian Kreil, Thomas Ernst, Thomas Schenk

Haematologica· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Thomas Ernst, Jana Hoffmann, Philipp Erben, Benjamin Hanfstein, Armin Leitner

Haematologica· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis.
Tomasz Sacha, Andreas Hochhaus, Benjamin Hanfstein, Martin C Müller, Zbigniew Rudzki

Leuk Res· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis